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Abstract
Interferon-a (IFN-a) is a natural choice for the treatment of hepatitis C, but half of the chronically infected individuals do not
achieve sustained clearance of hepatitis C virus (HCV) during treatment with IFN-a alone. The virus can impair IFN-a
signaling and cellular factors that have an effect on the viral life cycles. We found that the protein PCBP2 is down-regulated
in HCV-replicon containing cells (R1b). However, the effects and mechanisms of PCBP2 on HCV are unclear. To determine
the effect of PCBP2 on HCV, overexpression and knockdown of PCBP2 were performed in R1b cells. Interestingly, we found
that PCBP2 can facilitate the antiviral activity of IFN-a against HCV, although the RNA level of HCV was unaffected by either
the overexpression or absence of PCBP2 in R1b cells. RIP-qRT-PCR and RNA half-life further revealed that PCBP2 stabilizes
the mRNA of STAT1 and STAT2 through binding the 39Untranslated Region (UTR) of these two molecules, which are pivotal
for the IFN-a anti-HCV effect. RNA pull-down assay confirmed that there were binding sites located in the C-rich tracts in the
39UTR of their mRNAs. Stabilization of mRNA by PCBP2 leads to the increased protein expression of STAT1 and STAT2 and a
consistent increase of phosphorylated STAT1 and STAT2. These effects, in turn, enhance the antiviral effect of IFN-a. These
findings indicate that PCBP2 may play an important role in the IFN-a response against HCV and may benefit the HCV clinical
therapy.
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Introduction
Hepatitis C virus (HCV) infection is a major world health
problem with a worldwide carrier rate estimated at over 180
million people [1]. Persistently infected patients have a high risk of
contracting liver diseases. HCV infection leads to chronic hepatitis
in up to 60–80% of infected adults and then progresses to liver
cirrhosis and hepatocellular carcinoma [2]. Interferon-a (IFN-a)
has been shown to have beneficial effects in patients with chronic
hepatitis C. IFN-a, especially pegylated IFN-a therapy, leads to a
rapid decline in HCV RNA levels in serum, and long-term
responses to therapy are marked by the sustained reduction of
HCV RNA in the serum and liver, leading to resolution of chronic
Infection [3,4].
IFN-a possesses potent antiviral activity but does not act directly
on the virus or replication complex. Rather, it acts by inducing
IFN-stimulated genes (ISGs), that establish a non-virus-specific
antiviral state within the cell [5]. In brief, circulating IFN-a binds
to IFN cell surface receptor subunits. The binding leads to the
activation of the receptor associated Janus-activated kinase 1 (Jak1)
and tyrosine kinase 2 (Tyk2) [6,7]. The activated kinases
phosphorylate the signal transducer and activator of transcription
proteins 1 and 2 (STAT1 and STAT2). The activated STAT1/2
complex combines with IFN-regulatory factor 9 (IRF-9) to form a
complex that binds to the IFN-stimulated response elements on
cellular DNA, which leads to the expression of the multiple ISGs
[8]. Although IFN-a has been widely used to treat infected
patients, relapses are frequent even with the combination of
ribavirin, and more than half of those undergoing therapy remain
fail to clear the virus [9]. The factors responsible for the
persistence of HCV and the mechanisms by which HCV eludes
the active immune response have yet to be identified.
A number of the cellular proteins have been reported to
participate in the life cycle of HCV, such as cyclophilins [10,11],
which are essential for HCV replication and processing kinetics at
the NS5A-B site. As HCV is a positive-stranded RNA virus,
cellular RNA binding proteins (RBPs) are of particular importance
in its life cycle. RBPs have been shown to interact with the viral
ciselements. These RNA binding proteins include PTB [12,13],
HuR [14] and La antigen [15], all of which have been shown to be
involved in HCV IRES-mediated translation initiation or virus
genome replication. Poly(C) binding protein 2 (PCBP2, hnRNP
E2 or a-CP2) belongs to the hnRNP E family of RNA binding
proteins that interact with a sequence-specific motif with single-
stranded poly(C) tracts. In its cellular capacity, PCBP2 is involved
in posttranscriptional controls [16], protein interactions [17] and
decoy of microRNA [18]. Apart from its roles in maintaining
mRNA stability and regulating translation [19], PCBP2 can also
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including poliovirus [20,21], coxsackievirus [22], and rhinovirus
[23], which are positive sense RNA viruses structurally similar to
HCV, but which belong to the family Picornaviridae. Investigations
have demonstrated that PCBP2 can bind to the 59-UTR [24] and
39-UTR [25] regions of the HCV genome. These results suggest a
relationship between PCBP2 and HCV. However, conflicting data
exist as to how PCBP2 influences the HCV life cycle. Some
researchers have reported that PCBP2 is induced in Japanese
Fulminating Hepatitis-1 (JFH-1) infected cells and required for
JFH-1 replication [26]. Other studies report that PCBP2 and PTB
can rescue the inhibition of HCV IRES-mediated translation in
vitro [27], while other findings indicate that PCBP2 has no direct
effect on HCV replication or IRES-mediated translation
[24,25,28].
In this study, we used the classical HCV replicon cell model and
discovered significant down-regulation of PCBP2 in an HCV-
subgenome replicon containing Huh7.5.1 cells (R1b) compared to
naı ¨ve Huh7.5.1 cells. Although we experimentally validated that
PCBP2 had no direct effect on HCV as reported before [24,25],
we also observed that PCBP2 facilitates the antiviral activity of
IFN-a against HCV. Further investigations indicate that PCBP2
stabilizes the mRNA of STAT1 and STAT2 through binding the
C-rich tracts in the 39UTR of the two pivotal IFN-a signaling
pathway molecule. These findings suggest that PCBP2 plays an
important role in the cellular anti-HCV immune response. Further
knowledge of PCBP2 may benefit clinical HCV therapy.
Results
HCV non-structural proteins 4B and 5A inhibit the
expression of PCBP2 in R1b cells harboring the HCV
subgenome replicon
Sustaining viral replication with an HCV replicon in hepatoma
cells requires many host factors. Several RBPs are believed to be
essential in the replication and translation of HCV. We screened
the RNA expression level of RBPs by qRT-PCR. Most RBPs were
up-regulated or invariable (data not shown), while the mRNA level
PCBP2 presented an approximately 25% decrease in R1b cells
compared with Huh7.5.1 cells (Fig. 1A). Western blotting verified
Figure 1. HCV non-structural proteins 4B and 5A mediate the down-regulation of PCBP2 in R1b cells with HCV subgenomic
replicon. (A) qRT-PCR detection of PCBP2 mRNA level in Huh7.5.1 cells and R1b cells. The fold-relative enrichment was quantified with normalization
to the GAPDH level. The mRNA level of PCBP2 in Huh7.5.1 replicon cells is significantly lower compared with Huh7.5.1 cells (P,0.05). (B) Western
blotting indicates the down-regulation of PCBP2 protein level in R1b cells. (C) HCV non-structural protein NS4B and NS5A inhibit the expression of
PCBP2 in Huh7.5.1 cells. NS4B and NS5A lead to the down-regulated expression of PCBP2 while other NS proteins demonstrate no effect. (D) qRT-PCR
detection of PCBP2 mRNA level in Huh7.5.1 cells expressed HCV NS4B or NS5A proteins. NS4B demonstrate no effect on PCBP2 RNA level (P=0.72),
while NS5A can inhibit approximately 22% of PCBP2 RNA level. Each bar represents the average of triplicate data points with the standard deviation
represented as the error bar.* P,0.05 versus negative control.
doi:10.1371/journal.pone.0025419.g001
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in R1b cells (Fig. 1B). mRNA and protein levels of another RBP,
hnRNP A1, were not significantly different between the two cells.
As the main differences between the R1b cells and Huh7.5.1cells
were the HCV subgenome replicon and sequentially expressed
non-structural (NS) proteins, we speculated that HCV NS proteins
contributed to the decrease of PCBP2 in R1b cells. To verify the
observation,we constructed eukaryotic expression vectors for each
HCV NS protein. NS3 was fused with NS4A because NS4A is a
functional co-factor of NS3 and forms a noncovalent complex with
NS3 [29]. The PCBP2 protein changes were detected by Western
blotting after transfecting the recombinant plasmids into Huh7.5.1
cells (Fig. 1C). The PCBP2 protein level in cells with ectopic
expression of NS4B and NS5A decreased compared with the
pcDNA4 negative control, whereas no changes were observed in
the NS34A- and NS5B-expressing cells and negative control
compared with the untransfected cells. These results indicate that
NS4B and NS5A may contribute to the inhibition of PCBP2 in
R1b cells.
We further measured the PCBP2 mRNA level in cells with
ectopic expression of NS4B and NS5A by qRT-PCR. NS4B
demonstrated no effect on PCBP2 RNA level, but NS5A could
lower PCBP2 RNA level (Fig. 1D) by approximately 22%. These
results suggest that NS4B may post-transcriptionally regulate
PCBP2 while NS5A may function a transcriptional regulation.
IFN-a restores the expression level of PCBP2 in R1b cells
after inhibiting the expression of the HCV replicon
HCV replicons are sensitive to the antiviral program induced by
IFN-a. HCV protein and replicon RNA levels are reduced after
treatment with IFN-a in a dose-dependent manner [30]. To verify
if the inhibition of HCV protein can restore the expression of
PCBP2 in R1b cells, 100 IU/mL IFN-a was used to treat R1b
cells for 6 hours. After treatment with IFN-a, the PCBP2 level in
R1b cells increased to over 3.5-fold compared to untreated cells
(Fig. 2A) and the increase showed an IFN-a dose-dependent
manner (Fig. 2B). A slight decrease was observed in Huh7.5.1 cells
(Fig. 2A). Western blotting indicated that NS3 and NS5A
expression was dramatically reduced in cells treated with IFN-a
(concentration from 50 IU/mL to 200 IU/mL), whereas untreat-
ed control cells produced large amounts of HCV proteins (Fig. 2B).
STAT1 and STAT2 were used as markers to assess the biological
activity of the IFN-a preparation, and their expression were
correspondent with IFN-a dosage (Fig. 2B). To exclude the
possibility the lack of significant difference in PCBP2 was a
peculiarity of Huh7.5.1 cell, three additional hepatocyte-derived
cell lines (HepG2, SMMC7721 and LO2) were treated with IFN-
a. The PCBP2 protein levels were unchanged in those cells as
observed with the Huh7.5.1 cells (Fig. 2C).
When the R1b cells were treated with 1000 IU/mL IFN-a for
two weeks to obtain cured cells, complete clearance of HCV RNA
and proteins had occurred in the cells, and the PCBP2 levels were
restored to the same level as observed in non-infected Huh7.5.1
cells and did not recede to the lower levels, even if IFN-a was
removed from the media (Fig. 2D). These results demonstrate that
IFN-a can restore the normal PCBP2 level in R1b cells by
relieving the inhibition of the HCV NS proteins through clearance
of HCV from the cells.
PCBP2 facilitates the antiviral activity of IFN-a against
HCV in vivo
We have found that PCBP2 expression changes in R1b cells,
but what is the relationship between PCBP2 and HCV? To
illuminate that relationship, PCBP2 was overexpressed in R1b
cells (Fig. 3A, left panel). qRT-PCR was performed to measure the
HCV RNA level in cells. The HCV RNA level was unaffected by
PCBP2 overexpression compared with the negative control and
untransfected cells (Fig. 3A, right panel). However, when the
PCBP2-overexpressed R1b cells were treated with IFN-a for
12 hours, HCV RNA level decreased over 15% compared to
untransfected cells (Fig. 3B, left panel). Cells treated with IFN-a
combined with ribavirin presented an accordant tendency similar
to treatment with IFN-a alone (Fig. 3B, right panel). Ribavirin
monotherapy did not demonstrate any significantly different
influence in the PCBP2-overexpression cells compared with the
untransfected cells (Fig. 3B, middle panel).
To confirm the role of PCBP2 on the antiviral activity of IFN-a
against HCV, we performed PCBP2 knockdown. PCBP2 siRNA
was transfected into the R1b cells. An unrelated siRNA acted as a
negative control. Western blotting analysis revealed that the
siRNA depleted PCBP2 proteins over 90% compared with the
negative control and untransfected cells (Fig. 3C, left panel). As
expected, HCV RNA levels were stable in PCPB2-depleted cells
(Fig. 3C, right panel). However, depletion of PCBP2 also
apparently hampered the activity of IFN-a against HCV. HCV
RNA reduction in PCBP2-depleted cells decreased approximately
35% compared with untransfected cells (Fig. 3D, left panel). The
IFN-a and ribavirin combination results and ribavirin monother-
apy results further confirmed that PCBP2 affects IFN-a but has no
effect on ribavirin (Fig. 3D, middle and right panel). Taken
together, these results indicate that PCBP2 plays an important role
in the anti-HCV effects.
PCBP2 binds STAT1 and STAT2 mRNA and up-regulates
the expression of the two signal molecules
To elucidate how PCBP2 facilitates the biological activity of
IFN-a, we performed RNA Immunoprecipitation (RIP) to check if
any IFN-a signaling pathway factors are involved in the substrates
of PCBP2. Using streptavidin-sepharose beads, a complex of
biotinylated proteins with binding RNA could be isolated from
total cell lysate. Western blotting revealed that the RNP complex
containing biotinylated PCBP2 and GFP could bind to the beads
and be enriched (Fig. 4A). qRT-PCR was performed to check the
enrichment of binding RNA. GFP presents nonspecific binding of
RNA. a-globin and c-globin served as positive and negative
controls, respectively [31]. Lamin A/C represented an unrelated
mRNA [32]. The relative mRNAs levels were compared with the
RNA isolated from the PCBP2 RIP and GFP RIP by targeted
qRT-PCR and normalized to the c-globin mRNA levels. a-Globin
mRNA was enriched by nearly 5-fold in the PCBP2-RIP
compared to the GFP control. The enrichment of STAT1 and
STAT2 mRNAs corresponded to that of a-globin. However,
IRF9, JAK1 and TYK2 levels were significantly lower than that of
a-globin (Fig. 4B). Notably, we detected that HCV RNA was
enriched in the PCBP2 RNP complex. The results indicate that
the STAT1 and STAT2 mRNAs may be the substrates of PCBP2
and the effect on IFN-a may relate to the influence on STAT1 and
STAT2.
Whether the binding of mRNA to PCBP2 will lead to the
expression of proteins remain to be verified. PCBP2 was
overexpressed in R1b cells subsequently with treatment of IFN-
a. The expression of IFN-a pathway factors were detected by
Western blotting. IFN-a induced the expression of IRF9, STAT1
and STAT2, but exerted no influence on JAK1 and TYK2.
Overexpression of PCBP2 distinctly increased the STAT1 and
STAT2 protein levels in comparison to a negative control, while
no significant differences were observed with respect to IRF9,
PCBP2 Enhances the Activity of IFN-a against HCV
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consistent increase in phosphorylated STAT1 and STAT2, which
may due to the increase of total proteins. These data indicate that
PCBP2 binds the STAT1 and STAT2 mRNAs and up-regulates
their protein levels.
The C-rich tracts in the 39UTR of mRNA of STAT1 and
STAT2 are PCBP2 binding sites
In many cases, PCBP2 functions through binding the 39UTR of
target mRNA. As we found the STAT1 and STAT2 mRNA
interacted with PCBP2, we decided to test which regions of
STAT1 and STAT2 39-UTR interacted with PCBP2 by RNA
pull-down assay. Four fragments located in the 39UTR of STAT1
and STAT2 were inserted into a pGEM-3zf vector containing a
T7 promoter. These fragments were predicted as potential binding
sites by sequence analysis as they contained C-rich tracts
harboring the core binding sequence of PCBP2 [33]. The maps
of these regions are shown in Fig. 5A. The biotin-labeled RNA
probes corresponding to each fragment were synthesized in vitro
with T7 RNA polymerase. The pGEM-3zf vector sequence and
the a-globin 39-UTR were used as a non-specific control (NSC)
and a positive control, respectively. The proteins pulled down by
Figure 2. IFN-a restores the expression level of PCBP2 in R1b cells after inhibiting the expression of HCV replicon. (A) Western
blotting analysis indicated prominent up-regulation of PCBP2 in R1b cells after treated with 100 IU/mL IFN-a, while no significant differences were
noted in Huh7.5.1 cells. (B) The restoration of the expression of PCBP2 is IFN-a dosage dependent and due to inhibition of HCV NS proteins. IFN-a
doses of 50, 100 and 200 IU/mL were used to treat R1b cells for 6 hours. Western blotting was performed to detect the expression of proteins. (C)
PCBP2 protein level in other hepatocyte-derived cells after treatment of 100 IU/mL IFN-a. The PCBP2 level was unchanged, similar to that observed in
Huh7.5.1 cells. (D) The protein level of PCBP2 was restored in cured R1b cells. The PCBP2 level did not return to a low level when IFN-a was removed
from the media for a week.
doi:10.1371/journal.pone.0025419.g002
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PCBP2 antibody. PCBP2 was not detected in the NSC pull-down
complex. In contrast, the a-globin mRNA showed a strong
binding of PCBP2 (Fig. 5B, upper panel). As for the four probes,
the S13U2 and S23U1 probes presented significant linking
products accordant with a-globin (Fig. 5B, lower panel). S13U1
did not demonstrate binding of PCBP2, and S23U2 only had very
faint non-reproducible linking products. PTB is an important
HCV-related RBP that does not contain consensus PCBP2
binding sequences in its mRNA. We assayed PTB with the
RNA pull-down complex, and the results indicated that PTB did
not demonstrate any binding of the 39UTR of STAT1 and
STAT2. These data demonstrate that PCBP2 binding to the
39UTR of STAT1 and STAT2 is specific.
To further confirm whether the binding of PCBP2 to S13U2
and S23U1 is a specific result, a competition assay was performed.
Non-biotin labeled homologous probes (cold competitors) were
added to compete with biotin-labeled probes in PCBP2 interac-
tion. The cold competitors exhibited strong competition only at 5-
fold molar excess (Fig. 5C). Therefore, we conclude that the major
binding determinant of PCBP2 resides in the S13U2 and S23U1
fragments. The sequence of the two fragments is indicated in
Fig. 5D. The C-rich regions (underlined) bear a striking
resemblance to the C-rich motifs previously identified as the
PCBP2 binding site in human a-globin mRNA [31].
PCBP2 enhances the expression of STAT1 and STAT2
through stabilizing their mRNA
PCBP2 enhances the protein level of STAT1 and STAT2, and
it has been demonstrated that C-rich tracts in their 39UTR are the
binding sites of PCBP2. However, how PCBP2 affects mRNA
remains to be elucidated. The interaction of PCBP2 proteins with
the STAT1 and STAT2 mRNA suggests that control over their
mRNA levels might be mediated by an effect on mRNA stability.
qRT-PCR revealed an over 80% increase of STAT1 mRNA and
a 150% increase of STAT2 mRNA in PCBP2-overexpressed cells
compared with negative controls after treatment with IFN-a
(Fig. 6A). A RPA was carried out to verify the mRNA decay
course. RNA harvested at subsequent time points was quantified
for STAT1 and STAT2 mRNA levels by RPA analysis. PCBP2
overexpression and knockdown were performed in R1b cells. A
pcDEF vector and unrelated siRNA acted as negative controls,
respectively. This analysis revealed that the rates- of STAT1 and
STAT2 mRNA decay in negative control cells were similar, with
an average half-life of approximately 1.4 hours and approximately
1.7 hours respectively. In contrast, PCBP2 overexpression resulted
in prolongation of half-life to approximately 2.8 hours and
approximately 4.9 hours, while knockdown of PCBP2 shortened
their half-lives to approximately 1.1 hours and approximately
1.3 hours, respectively (Fig. 6B). This alteration in STAT1 and
STAT2 mRNA stability in the PCBP2 -overexpression cells was
consistent with the observed increase in their mRNA levels and
protein. The mRNA stabilization encouraged by PCBP2 supports
the up-regulation of STAT1and STAT2 proteins and accordingly
the effect on IFN-a.
Discussion
Cells harboring HCV replicons provide the basis for a long-
sought cellular system that allows detailed molecular studies of
HCV and the development of antiviral drugs [34]. In our work we
utilized the classical HCV replicon cellular system to examine the
molecular mechanism by which PCBP2 and IFN-a inhibit HCV.
The major novel findings in this work include the followings:
PCBP2 facilitates the antiviral activity of IFN-a against HCV,
STAT1 and STAT2 mRNA serve as binding substrates of PCBP2
and are stabilized by PCBP2. Here, we propose a model where
PCBP2 modulates the effects of IFN-a against HCV (Fig. 7). In
R1b cells, the HCV subgenomic replicon abundantly expresses
viral NS proteins. These NS proteins impair cellular molecules as
an attempt to resist host immune responses [35]. The NS-
mediated inhibition of PCBP2, as discovered in our work and
verified by ectopic expression of NS proteins in naı ¨ve Huh7.5.1
cells (Fig. 1), further supports the idea of NS proteins serving as
anti-host immunity proteins Investigations have supported the
point that viral NS proteins can degrade STAT1 [36] and STAT2
[37], or suppress STAT1 phosphorylation [38,39], which may
explain the extremely low expression levels of STAT1 and STAT2
in R1b cells (Fig. 2B). When exogenous IFN-a is added to treated
R1b cells, STAT1 and STAT2 are induced and promote
downstream ISGs expression that, in turn, inhibits HCV
expression. This relieves the inhibition of PCBP2 in R1b cells
(Fig. 2A). PCBP2 can facilitate the antiviral activity of IFN-a
against HCV (Fig. 3), which explains the inhibition of PCBP2
exerted by HCV NS proteins. RIP-qRT-PCR demonstrates the
mRNA of STAT1 and STAT2 are enriched in the PCBP2 RNP
complex, which implies that they are binding substrates of PCBP2
(Fig. 4B). Further studies confirm the poly-C tracts in the 39UTR
of STAT1 and STAT2 mRNAs are a PCBP2 binding site (Fig. 5).
The stability of the STAT1 and STAT2 mRNAs is increased as
evidenced by elongation of mRNA half-life (Fig. 6B) and leads to
the up-regulated protein level of the two signaling molecules
(Fig. 4C). As STAT1 and STAT2 play an indispensable role in
antiviral immunity against HCV expression, PCBP2 accordingly
facilitates the effects of IFN-a against HCV. In summary, these
factors interact with each other in HCV replicon cells and form a
loop pathway (Fig. 7).
PCBP2 has been demonstrated to influence the life cycles of
positive-stranded RNA viruses [21,22], but no direct effects has
been revealed in terms of an interaction with HCV. The binding
of PCBP2 to the HCV genome was verified in our studies, but the
mechanism and biological function of underlining the PCBP2-
HCV interaction remain to be explored. As many RBPs are
employed by HCV to promote translation or replication generally
through direct binding with HCV 59-o r3 9-UTR regions, the
PCBP2 facilitation of the effect of IFN-a against HCV illuminates
new RBPs characteristics that mediate the life processes of HCV.
Although ectopic expression of HCV NS proteins demonstrates
inhibition of PCBP2 in R1b cells, the regulation of PCBP2 is still
not clear. No evidence exists demonstrating how HCV NS
proteins can degrade PCBP2 mRNA or exert translation
Figure 3. PCBP2 enhances the antiviral activity of IFN-a against HCV. R1b cells were transfected with pcDEF-PCBP2 or PCBP2 siRNA.
48 hours after transfection, the cells were treated with 100 IU/mL IFN-a, 200 mM ribavirin or a combination of the two, for 12 hours. Western blotting
was used to check the overexpression or knockdown of PCBP2. qRT-PCR was performed to measure the HCV RNA level in the treated cells.
(A) Overexpression of PCBP2 alone did not have an impact on the HCV RNA level (P=0.13). (B) Overexpression of PCBP2 enhanced the inhibitory
effects of IFN-a against HCV but did not influence the antiviral effect of ribavirin. (C) Knockdown of PCBP2 alone did not have an impact on HCV RNA
level (P=0.28). (D) Knockdown of PCBP2 impaired the inhibition effect of IFN-a against HCV but did not influence the antiviral effect of ribavirin. Each
bar represents the average of triplicate data points with the standard deviation represented as the error bar.* P,0.05 versus negative control.
doi:10.1371/journal.pone.0025419.g003
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PLoS ONE | www.plosone.org 6 ber 2011 | Volume 6 | Issue | e25419 Octo 10Figure 4. PCBP2 enhances the effect of IFN-a through binding STAT1 and STAT2 mRNA and up-regulates the expression of the two
signal molecules in IFN-a pathway. RIP assay and targeted qRT-PCR confirmed the enrichment of different IFN-a signal pathway factor mRNAs in
the PCBP2-RNA complex. (A) Detection of the PCBP2-RNA complex precipitated with streptavidin beads using anti-PCBP2 or anti-GFP antibody and
streptavidin by Western blotting. (B) Targeted qRT-PCR was carried out on RNA isolated from RNP complexes precipitated in RIP assay. Analysis of
mRNAs isolated from a GFP RIP reaction was carried out in parallel as nonspecific binding. a-globin was used as positive control. The enrichment of
each mRNA was compared to the GFP control. Each bar represents the average of triplicate data points with standard deviation represented as the
error bar. (C) PCBP2 up-regulated the expression of STAT1 and STAT2 after the treatment of IFN-a while other factors remained intact. The R1b cells
were transfected with pcDEF vector or pcDEF-PCBP2. Forty-eight hours after transfection, the cells were treated with 100 IU/mL IFN-a and paired with
untrasfected cells. Next, 6 hours later, the cell lysates were assessed by Western blotting.
doi:10.1371/journal.pone.0025419.g004
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ERK1/2-PCBP2 pathway was
established in myeloid chronic myelogenous leukemia blast crisis
(CML-BC) progenitors [40]. In the cells, PCBP2 expression was
induced by BCR/ABL in a dose- and kinase-dependent manner
through constitutive activation of MAPK
ERK1/2. It is speculated
that HCV may impair this pathway and consequently inhibit the
expression of PCBP2. However, whether the pathway plays a role
in hepatoma cells harboring HCV replicon remains to be
examined.
The two most intensively studied posttranscriptional controls
mediated by PCBP2 are mRNA stabilization and translational
modulation. The initial mRNA identified as a PCBP2 stabilization
target was human a-globin mRNA. The 39-UTR of this mRNA led
to the identification of the corresponding RNP complex [31] that
forms at this site. In our experiments, a-globin was utilized as a
positive control and demonstrated a robust interaction with PCBP2.
S T A T 1a n dS T A T 2m R N Aw e r ev e r i f i e dt ob ei n v o l v e di nP C B P 2
containing complexes with long half-lives. These findings lead to a
model in which 39-UTR–PCBP2 complexes can serve as general
determinants of mRNA stability. Previous studies have revealed that
additional mRNAs, such as those encoding tyrosine hydroxylase [41]
and lipoxygenase have closely related [42], if not identical, PCBP
containing 39-UTR complexes. It is also known that PCBP2 mRNA
itself is represented in PCBP2-RNP complexes, suggesting autoreg-
ulatory control of PCBP2 expression [31]. However, as the
corresponding mechanisms involved in the proposed autoregulation
of PCBP2 expression are still to be elucidated, additional experiments
are required to prove that this mechanism is used by HCV to reduce
PCBP2 expression.
Although IFN-a was applied as a treatment of HCV as a crucial
mediator of the innate antiviral immune response for decades,
treatment with IFN-a alone has achieved only modest success, and
half of the infected individuals with chronic disease do not achieve
sustained clearance of HCV [5]. Abnormalities in the downstream
actions of IFN-a activity mediated by HCV have been indicated in
several studies. These findings provide a biological basis for
correlations between the HCV NS proteins and the lack of response
to IFN-a therapy [35,36,38,39]. However, the cellular factors
participating in IFN-a antiviral response are still unclear. Identifica-
tion of the host factors that can predict sustained virological response
(SVR) will undoubtedly improve the treatment of hepatitis C. We
have found that PCBP2 plays an important role in influencing anti-
HCV IFN-a.HighlevelsofPCBP2resultinamorepowerfuleffectof
IFN-a in HCV replicon cells, while the absence of PCBP2 impairs
that effect. If the PCBP2 level corresponds to the virological response
of IFN-a in HCV clinical therapy, itmay be a prospective marker for
clinical diagnosis for using IFN-a.
We have demonstrated that STAT1 and STAT2 were involved
in the action of PCBP2 on IFN-a. The mRNA of some ISGs, such
as IRF9, JAK1 and TYK2, were also assayed in the RNP complex
obtained in RIP assay. Despite their mRNA being enriched in the
PCBP2 complex compared to the GFP complex, their protein
levels were not affected by PCBP2. The binding of their mRNA to
PCBP2 may represent nonspecific binding. Other important ISGs,
for example PRKR, Mx1, OAS2 and ADAR1, are important for
the antiviral activity of IFN-a [43]. Whether PCBP2 could affect
their mRNA and, correspondingly the antiviral activity of IFN-a is
of interest and remains to be investigated.
In conclusion, our work reveals a new mechanism elucidating
how RNA-binding proteins interact with HCV, and more
importantly, these findings suggest the inclusion of clinically
relevant PCBP2 in the HCV therapy.
Materials and Methods
Cell culture and cell lines
Huh7.5.1 human hepatoma cells, kindly provided by Francis
Chisari (Scripps Research Institute, La Jolla), were maintained in
complete DMEM supplemented with 2 mM L-glutamine, 100 U/
ml of penicillin, 100 mg/ml of streptomycin and 10% FBS.
HepG2 (ATCC), SMMC7721 [44] and LO2 [45] were main-
tained in MEM and RPMI1640 medium with the same
supplements described above, respectively. R1b cells were HCV
1b subgenome replicon harboring Huh7.5.1 cells developed in our
laboratory as described previously [34] and maintained with an
additional 500 mg/mL G418 supplement. To prepare cured cells
[46], the R1b cells were treated with 1000 IU/ml of IFN-a in the
absence of G418. The treatment was continued for 2 weeks with
the addition of IFN-a at 3-day intervals. qRT-PCR confirmed the
clearance of HCV RNA in these cured cells.
Ectopic expression of HCV NS proteins
HCV NS3-, NS4A-, NS4B-, NS5A- and NS5B-encoding
fragments were amplified from a plasmid containing the HCV
genome and inserted into a pcDNA4-myc vector (Invitrogen),
respectively. The plasmids were transfected into Huh7.5.1 cells
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. The protein lysates were analyzed by Western
blotting using anti-myc tag antibody to detect the expression of NS
proteins.
IFN-a treatment of cells with overexpression or
knockdown of PCBP2
R1b cells were transfected with either siRNA targeting PCPB2
[47] or a pcDEF-PCBP2 plasmid using Lipofectamine 2000. Non-
related siRNA and pcDEF-myc vector were used as negative
controls. The siRNA sequences designed to silence PCBP2 gene
expression and a non-related control were 59-GGCCTATAC-
CATTCAAGGA-39 and 59–ACGUGACACGUUCGGAGA
ATT–39, respectively. Twenty-four hours after transfection, the
cells were treated with 100 IU/mL IFN-a or 200 mM Ribavirin
and were harvested 6 hours later. The cells were lysed in cell lysis
buffer for western blotting analysis to examine the expression levels
of various proteins or in Trizol (Invitrogen) for qRT-PCR analysis
to check the HCV RNA level.
Western blotting
Western blotting was performed following a previously
described method [32]. Total protein was extracted with lysis
Figure 5. The C-rich tracts in the 39UTR of mRNA of STAT1 and STAT2 are PCBP2 binding sites. (A) Fragments of the STAT1 and STAT2 39-
UTR used in synthesis of sense RNA probe in vitro and sequences position in the 39-UTR. (B) RNA pull-down assay using the four probes of STAT1 and
STAT2. Cytoplasmic extracts from 100 IU/mL IFN-a treated R1b cells were incubated with biotin-labeled RNA probes. The mixture was pulled down by
streptavidin beads. The resulting complexes were separated by SDS-PAGE and detected by Western blotting. A pGEM-3zf vector sequence was
utilized as a nonspecific control (NSC), and the a-globin 39-UTR was utilized as a positive control. The bottom panel depicts the assay results with the
RNAs set of fragments shown in A. (C) 2-fold, 5-fold and 10-fold of excess unlabeled cold probes were added to compete with the labeled probes for
competition analysis. The results indicate that 5-fold cold competitors of S13U2 and S23U1 probe exhibited strong competition. (D) The nucleotide
sequences of S13U2 and S23U1. The CU-rich patches are underlined.
doi:10.1371/journal.pone.0025419.g005
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PLoS ONE | www.plosone.org 9 ber 2011 | Volume 6 | Issue | e25419 Octo 10Figure 6. The STAT1 and STAT2 mRNA is stabilized in cells overexpressing PCBP2. (A) qRT-PCR was carried out to measure mRNA level of
STAT1 and STAT2 after 6 hours of IFN-a treatment. R1b cells were untransfected or transfected with pcDEF-PCBP2. Each bar represents the average of
triplicate data points with the standard deviation represented as the error bar.* * P,0.001 versus untransfection. (B) RPA and RNA half-life analysis was
performed to monitor the STAT1 and STAT2 mRNA decay course. Two days after transfection, IFN-a was added and 6 hours later actinomycin D was
added to inhibit transcription. Representative blots are shown in the left panel and the mRNA levels were quantified through densitometric scanning.
For each set of RPAs, the band intensity at the 0 h time point was set to 100%, and the percentage of mRNA of remaining at the 2, 4 and 6 hour time
point was plotted shown in the right panel.
doi:10.1371/journal.pone.0025419.g006
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supplemented with protease inhibitors (2 mg/ml leupeptin, 2 mg/
ml pepstain, 2 mg/ml aprotinin and 2 mg/ml PMSF). The lysate
was separated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis, and the gel was transferred onto nitrocellulose
membrane. Antibodies against corresponding proteins were used
in proper dilution to detect the protein level. Specific primary
antibodies were obtained from the following sources: The PCBP2
antibody obtained from Aviva. The STAT1, STAT2, IRF9,
JAK1, TYK2 and hnRNP A1 antibodies were from Santa Cruz
Biotechnology. The HCV NS3 and NS5A antibodies were from
Virostat. phosphorylated-STAT1 and phosphorylated-STAT2
were obtained from Cell Signaling Technology. The PTB
antiserum was developed in our laboratory.
qRT-PCR
qRT-PCR was performed following a previously described
method [32]. In brief, qRT-PCR analysis was performed in an
ABI 7500 Sequence Detection System (Applied Biosystems) as
follows: 1 minute at 95uC, 40 cycles of 10 seconds at 95uC and
34 seconds at 60uC. The primers are described in detail in Table
S1. The fold-relative enrichment was quantified with normaliza-
tion to the GAPDH level.
RNA immunoprecipitation (RIP)
RIP was performed following a previously described method
[48]. In brief, a tandem affinity purified tag, Biotin-acceptor-
peptide (BAP), was fused to the 59-terminal of the encoding
sequences of PCBP2 and GFP, which were co-transfected with
BirA (biotin ligase) into R1b cells using Lipofectamine 2000.
Following that, 1 mM biotin and 100 IU/mL IFN-a were added
in the culture medium immediately after transfection. Forty-eight
hours later, the biotinylated-tagged proteins and RNA complex
were isolated from cell lysate using high affinity streptavidin-
sepharose beads (GE Healthcare). RNP was eluted from the beads
and the RNA was purified from RNP using Trizol. cDNA was
synthesized from the isolated RNA and then subjected to qRT-
PCR for detection of RNA enrichment using the primer sets
described in Table S1.
In vitro transcription
The sense RNA probes S13U1, S13U2, S23U1, S23U2 and a-
globin were synthesized by in vitro transcription using T7 RNA
polymerase (Takara). A nonspecific probe was synthesized from
the pGEM vector. To generate biotin-labeled RNA transcripts,
1 mg of each DNA template was added to in vitro transcription
reactions containing biotin-UTP (Roche). Non-labeled competitor
RNA probes were synthesized with unlabeled UTP. After
purification and removal of unincorporated nucleotides [49], the
RNA was resuspended in Buffer A (50 mM potassium acetate,
3 mM magnesium acetate, 2 mM dithiothreitol, 20 mM HEPES,
pH 7.4). Anti-sense RNA probes were synthesized using SP6 RNA
polymerase (Takara) following the same methods as used for the
sense RNA probes.
Biotin-RNA pull down
The biotin-labeled sense RNA probes were synthesized in vitro
using T7 RNA polymerase. Cytoplasmic cell extracts were isolated
from R1b cells treated with 100 IU/mL IFN-a. RNA affinity
capture was subsequently carried out with streptavidin-sepharose
beads as described previously [50]. The elutes were separated on
10% SDS-PAGE for PCBP2 detection by Western blotting. For
competition analysis, 2-fold, 5-fold and 10-fold of excesses
unlabeled cold competition RNAs were added to compete with
the labeled RNAs.
mRNA half-life and RNase protection assay (RPA)
RPA was performed as reported in detail previously [51] with
some minor modifications. Briefly, biotin-labeled antisense probes
were synthesized in vitro with SP6 RNA polymerase (Takara) from
DNA templates constructed for an RNA pull-down assay. Next,
Figure 7. Model of PCBP2-modulating effect of IFN-a against HCV. PCBP2 enhances the antiviral activity of IFN-a through stabilizing the
mRNA of STAT1 and STAT2. This accordingly, increases the protein level of the two molecules. The protein level increase also enhances the effect of
IFN-a against HCV.
doi:10.1371/journal.pone.0025419.g007
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transfection and 4 hours later Actinomycin D (Sigma, 5 mg/ml)
was added. The total RNA was collected at subsequent 0, 2, 4 and
6 hour time points. Ten micrograms of total RNA from each time
point sample was cohybridized with the antisense probes at 45uC
overnight. The excess probes and unhybridized RNA were
eliminated by treatment with RNase A/T1 (Ambion). The
precipitated protected RNA fragments were resolved on a 6%
polyacrylamide gel containing 8 M urea and then electrophoret-
ically transferred to a positively charged nylon membrane. The
membrane was used directly to detect the protection fragments
using a Chemiluminescent Nucleic Acid Detection Kit (Pierce)
according to the manufacturer’s instructions. Quantitation was
performed via densitometric scanning with Quantity One software
(BioRad).
Statistical analysis
All the experiments were performed three times and the data
are presented as the mean 63 standard deviations (SD). The
results were analyzed using a paired Student’s t test to determine
the significance of observed differences between the control and
individual treatment values. P,0.05 was regarded as statistically
significant.
Supporting Information
Table S1 RIP-qRT-PCR Primers. The primer sets of mRNAs
detected in qRT-PCR assay are listed in the table.
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